Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FATA-GIM3: Adjuvant Aromatase Inhibitors Upfront vs Sequential
NCT00541086Phase 3Unknown
- Sponsor
- Gruppo Italiano Mammella
- Start
- Mar 2007
- Primary completion
- Jul 2020
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anastrozole, letrozole and exemestane in breast cancer (6 arms), sponsored by Gruppo Italiano Mammella. Primary endpoint: Disease-free survival at 5 years. Status: unknown.
02
Drugs
anastrozoleletrozoleexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00541086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00541086.